Cargando…

O7.3. DOSE-RESPONSE META-ANALYSIS TO IDENTIFY THE OPTIMUM AND EQUIVALENT DOSES OF ANTIPSYCHOTIC DRUGS FOR SCHIZOPHRENIA

BACKGROUND: It is important to better understand the optimum doses and equivalent doses of antipsychotic drugs. Several methods to understand these relationships have been published, but all these methods have weaknesses. In this paper we present a dose-response meta-analysis which theoretically is...

Descripción completa

Detalles Bibliográficos
Autores principales: Leucht, Stefan, Crippa, Alessio, Orsini, Nicola, Davis, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888533/
http://dx.doi.org/10.1093/schbul/sby015.232
_version_ 1783312544563200000
author Leucht, Stefan
Crippa, Alessio
Orsini, Nicola
Davis, John
author_facet Leucht, Stefan
Crippa, Alessio
Orsini, Nicola
Davis, John
author_sort Leucht, Stefan
collection PubMed
description BACKGROUND: It is important to better understand the optimum doses and equivalent doses of antipsychotic drugs. Several methods to understand these relationships have been published, but all these methods have weaknesses. In this paper we present a dose-response meta-analysis which theoretically is the most appropriate method for this purpose. METHODS: We identified all double-blind, placebo-controlled, studies that compared at least two fixed doses of second-generation antipsychotic drugs or haloperidol in people with acute schizophrenia or with predominant negative symptoms. For this purpose, we searched multiple electronic databases, the website of the FDA, and the clinical trial database clinicaltrials.gov. The method applied was dose response meta-analyses with a spline model. The outcome was the reduction of the PANSS or BPRS total score from baseline or – for negative symptoms - a negative symptom scale. With this method we identified 95% effective doses (these have also been called “near-to-maximum” doses). We applied linear splines to examine whether the dose-response curves had already reached a plateau. Moreover, the identified dose-response relationships of each drug were used to derive risperidone equivalent doses. RESULTS: We identified 67 randomized-controlled trials that were eligible. The following 1mg risperidone equivalent doses were identified: amisulpride 86.6mg/day, aripiprazole 1.9mg/day, asenapine 2.4mg, brexpiprazole 0.56mg clozapine 91mg, haloperidol 1.01mg, iloperidone 3.2mg, lurasidone 23.5mg, olanzapine 2.4mg, paliperidone 13.4/2.1, quetiapine 77mg, risperidone 1mg, sertindole 3.6mg, ziprasidone 30mg. DISCUSSION: From a conceptual point of view, dose-response meta-analysis is the most appropriate method to identify maximally effective doses and equivalent doses. The results of this meta-analysis will be compared with other published methods to define dose-response, in particular the minimum-effective dose method, the classical mean dose method, the daily-defined-doses (DDD) method and expert consensus methods. The results of this analysis are likely to provide information with impact for treatment decisions.
format Online
Article
Text
id pubmed-5888533
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-58885332018-04-11 O7.3. DOSE-RESPONSE META-ANALYSIS TO IDENTIFY THE OPTIMUM AND EQUIVALENT DOSES OF ANTIPSYCHOTIC DRUGS FOR SCHIZOPHRENIA Leucht, Stefan Crippa, Alessio Orsini, Nicola Davis, John Schizophr Bull Abstracts BACKGROUND: It is important to better understand the optimum doses and equivalent doses of antipsychotic drugs. Several methods to understand these relationships have been published, but all these methods have weaknesses. In this paper we present a dose-response meta-analysis which theoretically is the most appropriate method for this purpose. METHODS: We identified all double-blind, placebo-controlled, studies that compared at least two fixed doses of second-generation antipsychotic drugs or haloperidol in people with acute schizophrenia or with predominant negative symptoms. For this purpose, we searched multiple electronic databases, the website of the FDA, and the clinical trial database clinicaltrials.gov. The method applied was dose response meta-analyses with a spline model. The outcome was the reduction of the PANSS or BPRS total score from baseline or – for negative symptoms - a negative symptom scale. With this method we identified 95% effective doses (these have also been called “near-to-maximum” doses). We applied linear splines to examine whether the dose-response curves had already reached a plateau. Moreover, the identified dose-response relationships of each drug were used to derive risperidone equivalent doses. RESULTS: We identified 67 randomized-controlled trials that were eligible. The following 1mg risperidone equivalent doses were identified: amisulpride 86.6mg/day, aripiprazole 1.9mg/day, asenapine 2.4mg, brexpiprazole 0.56mg clozapine 91mg, haloperidol 1.01mg, iloperidone 3.2mg, lurasidone 23.5mg, olanzapine 2.4mg, paliperidone 13.4/2.1, quetiapine 77mg, risperidone 1mg, sertindole 3.6mg, ziprasidone 30mg. DISCUSSION: From a conceptual point of view, dose-response meta-analysis is the most appropriate method to identify maximally effective doses and equivalent doses. The results of this meta-analysis will be compared with other published methods to define dose-response, in particular the minimum-effective dose method, the classical mean dose method, the daily-defined-doses (DDD) method and expert consensus methods. The results of this analysis are likely to provide information with impact for treatment decisions. Oxford University Press 2018-04 2018-04-01 /pmc/articles/PMC5888533/ http://dx.doi.org/10.1093/schbul/sby015.232 Text en © Maryland Psychiatric Research Center 2018. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstracts
Leucht, Stefan
Crippa, Alessio
Orsini, Nicola
Davis, John
O7.3. DOSE-RESPONSE META-ANALYSIS TO IDENTIFY THE OPTIMUM AND EQUIVALENT DOSES OF ANTIPSYCHOTIC DRUGS FOR SCHIZOPHRENIA
title O7.3. DOSE-RESPONSE META-ANALYSIS TO IDENTIFY THE OPTIMUM AND EQUIVALENT DOSES OF ANTIPSYCHOTIC DRUGS FOR SCHIZOPHRENIA
title_full O7.3. DOSE-RESPONSE META-ANALYSIS TO IDENTIFY THE OPTIMUM AND EQUIVALENT DOSES OF ANTIPSYCHOTIC DRUGS FOR SCHIZOPHRENIA
title_fullStr O7.3. DOSE-RESPONSE META-ANALYSIS TO IDENTIFY THE OPTIMUM AND EQUIVALENT DOSES OF ANTIPSYCHOTIC DRUGS FOR SCHIZOPHRENIA
title_full_unstemmed O7.3. DOSE-RESPONSE META-ANALYSIS TO IDENTIFY THE OPTIMUM AND EQUIVALENT DOSES OF ANTIPSYCHOTIC DRUGS FOR SCHIZOPHRENIA
title_short O7.3. DOSE-RESPONSE META-ANALYSIS TO IDENTIFY THE OPTIMUM AND EQUIVALENT DOSES OF ANTIPSYCHOTIC DRUGS FOR SCHIZOPHRENIA
title_sort o7.3. dose-response meta-analysis to identify the optimum and equivalent doses of antipsychotic drugs for schizophrenia
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888533/
http://dx.doi.org/10.1093/schbul/sby015.232
work_keys_str_mv AT leuchtstefan o73doseresponsemetaanalysistoidentifytheoptimumandequivalentdosesofantipsychoticdrugsforschizophrenia
AT crippaalessio o73doseresponsemetaanalysistoidentifytheoptimumandequivalentdosesofantipsychoticdrugsforschizophrenia
AT orsininicola o73doseresponsemetaanalysistoidentifytheoptimumandequivalentdosesofantipsychoticdrugsforschizophrenia
AT davisjohn o73doseresponsemetaanalysistoidentifytheoptimumandequivalentdosesofantipsychoticdrugsforschizophrenia